Oncogene forms marketing alliance in Japan:
This article was originally published in Clinica
Oncogene Science Diagnostics has formed a four-year alliance with Tokyo-based company Fujirebio to develop, manufacture and sell cancer diagnostic products in Japan. Fujirebio has received a non-exclusive licence to develop a range of cancer assays based on Oncogene's proprietary technology. The assays will be formatted on Fujirebio's automated clinical system, Lumipulse. The Uniondale, New York-based company will receive royalties on product sales, licensing fees and R&D funding. Oncogene expects the launch of the first newly-developed assay later next year.